European Committee for Treatment & Research in Multiple Sclerosis

Startseite
Schweiz
Basel
European Committee for Treatment & Research in Multiple Sclerosis

The European Committee for Treatment & Research in Multiple Sclerosis - the world's largest organisat

SAVE THE DATE: MSMilan2023, the 9th joint ECTRIMS-ACTRIMS meeting, will be held as a hybrid event on 11–13 October in Milan, Italy

03/12/2025

Our global community came together at Patient Community Day in record numbers — today, we are proud to share the impact.

The PCD 2025 Impact Report highlights an exceptional year of global connection, scientific exchange, and shared learning. This year, 2,383 people living with MS, NMOSD, and MOGAD from 89 countries joined us online and in Barcelona to learn, ask questions, and share their lived experience.

Access the report here: https://www.ectrimspatientcommunity.eu/impact-report/

Inside the PCD Impact Report:
• Key scientific insights presented by world-leading experts
• Perspectives from our first People with Lived Experience Panel
• Interviews with patient advocacy leaders, clinicians, researchers, and people living with MS, NMOSD, and MOGAD

Explore the report and discover how Patient Community Day is shaping the future of MS research, treatment, and care.

28/11/2025

🏥 Join our upcoming Clinical Case NeuroWebinar!

This session will focus on the multifactorial decision-making process involved in choosing the optimal treatments for individuals with NMOSD.

Tania Kümpfel and Daniel Engels from the Ludwig-Maximilians-Universität München will present a compelling clinical case, then delve into the risks and benefits of NMOSD therapy. They will also highlight the reasons and challenges behind switching NMOSD treatments — from disease activity and infections to older age and comorbidities.

Gain valuable insights from leading experts and deepen your understanding of the key factors shaping NMOSD treatment decisions.

🗓️Tuesday, 9 December
🕕 18:00 - 19:00 CET

Register for FREE via myECTRIMS: https://my.ectrims.eu/webinars/111

27/11/2025

⏰ Four Days Left!

This is your final reminder to apply for the 2026 ECTRIMS Fellowship Programmes. Don’t miss this exceptional opportunity to advance your career in MS, MOGAD, and NMOSD research, guided by leading experts in the field.

📅 Deadline: 1 December 2025, 23:59 CET
🎯 Submit your application now: ectrims.eu/fellowships

Take the next step in shaping the future of MS research and care!

25/11/2025

Special MS | Professor Bruno Stankoff, President of ECTRIMS on the 2024 McDonald Criteria and the Future of MS Diagnosis

Read it here:🔗https://ectrims.eu/insights/a-rupture-with-the-past-ectrims-president-on-the-2024-mcdonald-criteria-and-the-future-of-ms-diagnosis/

Professor Stankoff from Sorbonne Université and Hôpital Pitié Salpêtrière, AP-HP walks us through the most crucial innovations that underpin the 2024 revisions to the McDonald Criteria.

These updates mark a defining moment in MS diagnosis – a move toward a single, universally applicable framework. The result is a more specific and timely approach to diagnosis, adaptable across all disease forms, ages, and clinical contexts.

24/11/2025

Best of : Therapy Highlight

In a study presented by Prof Michel of Nantes Université using data from the French MS registry (>10,000 patients), high-efficacy therapies were shown to better control disability linked to relapses than moderate-efficacy therapies—but did not significantly delay progression independent of relapses and MRI activity (PIRMA) compared to moderate-efficacy therapies.

📌 Explore the Therapy Track and all highlights in the Best of ECTRIMS 2025 Slide Deck on myECTRIMS: https://my.ectrims.eu/bestofslidedecks

21/11/2025

🎥 Revisit one of the most clinically insightful sessions from !

✨ Scientific Session 5: Personalised Treatment Regimes in MS and Related Disorders. This session explored tailored therapeutic strategies in MS, NMOSD, MOGAD, and paediatric patients, highlighting the latest evidence on dosing, treatment discontinuation, and long-term outcomes.

Key highlights included:
• Efficacy, effectiveness, and safety of HET with different intervals and doses in MS — Fredrik Piehl from the Karolinska Institutet
• Extending dosing intervals safely in NMOSD and MOGAD — Ho Jin Kim
• Progression independent of relapse and MRI activity: insights from the French MS Registry — Laure Michel from CHU de Rennes

▶️ Watch the session replay now: https://ectrims-congress.virtual-meeting.org/programme/session/67919

18/11/2025

New Highlights: This webinar focuses on the synergetic effects of DMTs and rehabilitation in MS. While DMTs reduce inflammation and relapses, rehabilitation helps restore and preserve daily abilities.

Read the key highlights here: https://ectrims.eu/insights/webinar-highlights-dmts-and-rehab-in-ms/
Watch the full webinar replay here: https://my.ectrims.eu/programme/session/69088

Organised in collaboration with RiMS - Rehabilitation in Multiple Sclerosis, this webinar explores how rehabilitation and DMTs can work in harmony to slow MS progression, enhance neurological reserve, improve quality of life, and support a brain-healthy state.

Don’t miss the key takeaways from our expert panel:
- Prof. Peter Heys of Universiteit Hasselt
- Prof. Emilio Portaccio of Università degli Studi di Firenze
- Prof. Michelle Ploughman of Memorial University, Newfoundland and Labrador
- Prof. Ulrik Dalgas of Aarhus Universitet

17/11/2025

📢 New in Multiple Sclerosis Journals: A cross-sectional case–control study within the US Network of Pediatric MS Centers - led by Jennifer Graves (UC San Diego & Rady Children's Hospital-San Diego) - found no correlation between epigenetic clocks and telomere length, indicating that these measures reflect distinct and complementary dimensions of biological aging in MS.

Read more here: https://journals.sagepub.com/doi/10.1177/13524585251386217

13/11/2025

🎙️ “There isn’t a part of the patient’s MS journey that isn’t touched by nurses — from diagnosis and treatment to aging and rehabilitation.” — Amy Perrin Ross, MS Specialist Nurse and Program Coordinator, Loyola University Chicago

Nurses are at the centre of MS care — guiding patients, coordinating teams, and translating complex science into meaningful support.

In this special podcast episode, Amy Perrin Ross and Miguel Ángel Cortés from Vall d'Hebron Barcelona Hospital Campus discuss how MS nurses combine listening, leadership, and technology to advance patient-centred care.

🎧 Listen now:

🔹 Spotify: https://bit.ly/4hY4bsQ
🔹 Apple Podcasts: https://apple.co/49RE0Sv
🔹 ECTRIMS Website: https://bit.ly/4nMhRIx

13/11/2025

🚨 Time is running out!

Only two weeks left to apply for the 2025 ECTRIMS Fellowship Programmes — a unique opportunity to advance your career in multiple sclerosis research and care, supported by leading experts in the field.

💡 Why apply?

ECTRIMS offers five exclusive fellowships, each providing an annual stipend of up to €55,000, empowering early-career researchers and clinicians to make a lasting impact in MS research and patient care.

🌍 Who can apply?

We welcome applications from young professionals in MS research and care who meet the programme criteria. Gain valuable insights, expand your professional network, and contribute to the future of the MS community.

📅 Deadline: 1 December 2025, 23:59 CET
📖 Learn more and apply 👉 https://ectrims.eu/fellowships

12/11/2025

Join today our Clinical Case NeuroWebinar!

In this interactive session, our expert panel will explore one of the most intriguing challenges in MS management:
How should we approach treatment when patients remain clinically and radiologically stable, yet show persistently elevated NfL levels?

🧠 Rina Demjaha from Medizinische Universität Graz will open with a detailed case study of a 40-year-old MS patient who remains clinically stable on platform therapy and shows no new MRI activity, yet presents with consistently elevated serum NfL levels — prompting key questions about treatment adequacy.

🔍 Michael Khalil from Medizinische Universität Graz will then guide us through the decision-making process in such complex situations, discussing the implications of persistent NfL elevation and whether continued monitoring or treatment modification is the best course of action.

💬 Participants will have the opportunity to submit questions and engage in a live exchange with our panelists.

📅 12 November 2025
🕕 18:00-19:00 CET

Register for free via myECTRIMS 👉 https://my.ectrims.eu/webinars/110

10/11/2025

👀 New MS : Optic Nerve Assessment in MS

The optic nerve has become the fifth anatomical location in the 2024 revisions of the McDonald criteria for MS. Why is it of particular interest and how can it be assessed?

Read it here: https://ectrims.eu/insights/redefining-diagnostic-boundaries-optic-nerve-assessment-in-ms/

Featured in this month's article:

➡️ Shiv Saidha of Johns Hopkins University tells us, "Almost everybody is familiar with MRI. There is perhaps less familiarity with OCT. OCT is quick, inexpensive, and easy to repeat. With a resolution of approximately 3–5 microns, it provides an almost virtual biopsy of the retina."

➡️ Jeffrey Cohen of Cleveland Clinic Mellen Center for MS Treatment and Research adds, "The visual system is frequently affected in MS. Both the afferent and efferent visual pathways are involved in the disease process. Vision plays a crucial role in daily functioning, and its impairment can have a profound impact on an individual’s ability to work and overall quality of life."

Adresse

Reinacherstrasse 131
Basel
4053

Telefon

+41616867777

Webseite

http://www.ectrims.eu/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von European Committee for Treatment & Research in Multiple Sclerosis erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.